Your browser doesn't support javascript.
loading
Oncogenic CDK13 mutations impede nuclear RNA surveillance.
Insco, Megan L; Abraham, Brian J; Dubbury, Sara J; Kaltheuner, Ines H; Dust, Sofia; Wu, Constance; Chen, Kevin Y; Liu, David; Bellaousov, Stanislav; Cox, Anna M; Martin, Benjamin J E; Zhang, Tongwu; Ludwig, Calvin G; Fabo, Tania; Modhurima, Rodsy; Esgdaille, Dakarai E; Henriques, Telmo; Brown, Kevin M; Chanock, Stephen J; Geyer, Matthias; Adelman, Karen; Sharp, Phillip A; Young, Richard A; Boutz, Paul L; Zon, Leonard I.
Afiliação
  • Insco ML; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Abraham BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Dubbury SJ; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Kaltheuner IH; The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Dust S; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Wu C; Institute of Structural Biology, University of Bonn, 53127 Bonn, Germany.
  • Chen KY; Institute of Structural Biology, University of Bonn, 53127 Bonn, Germany.
  • Liu D; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Bellaousov S; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Cox AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Martin BJE; University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
  • Zhang T; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Ludwig CG; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
  • Fabo T; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
  • Modhurima R; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Esgdaille DE; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Henriques T; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Brown KM; University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
  • Chanock SJ; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
  • Geyer M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
  • Adelman K; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
  • Sharp PA; Institute of Structural Biology, University of Bonn, 53127 Bonn, Germany.
  • Young RA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
  • Boutz PL; The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Zon LI; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Science ; 380(6642): eabn7625, 2023 04 21.
Article em En | MEDLINE | ID: mdl-37079685
RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We found that disrupted nuclear RNA surveillance is oncogenic. Cyclin-dependent kinase 13 (CDK13) is mutated in melanoma, and patient-mutated CDK13 accelerates zebrafish melanoma. CDK13 mutation causes aberrant RNA stabilization. CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Forced aberrant RNA expression accelerates melanoma in zebrafish. We found recurrent mutations in genes encoding nuclear RNA surveillance components in many malignancies, establishing nuclear RNA surveillance as a tumor-suppressive pathway. Activating nuclear RNA surveillance is crucial to avoid accumulation of aberrant RNAs and their ensuing consequences in development and disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinógenos / RNA Nuclear / Proteína Quinase CDC2 / Estabilidade de RNA / Melanoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinógenos / RNA Nuclear / Proteína Quinase CDC2 / Estabilidade de RNA / Melanoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article